Jeffrey Ubben

2017-07-alpha-stephen-taub-value-act-valeant-pharmaceuticals-small.jpg

Premium

Jeffrey Ubben’s ValueAct Continues to Surge Despite its Valeant Stake

The activist firm’s flagship hedge fund is still up for the year despite still holding shares of the embattled drugmaker.

Stephen Taub

July 14, 2017

Portfolio

The Morning Brief: Corporate Execs, ValueAct’s Ubben Unveil Governance Principles

Amanda Cantrell

July 22, 2016

Premium

ValueAct’s Valeant Problem

Jeffrey Ubben’s activist firm built its fortunes in part based on its early success with now-struggling Valeant Pharmaceuticals International. With Valeant battling a 90 percent drop in its share price, can ValueAct outrun collateral damage to its reputation?

July 21, 2016

Portfolio

The Morning Brief: Valeant Surges, but Big Problems Remain

Stephen Taub

March 22, 2016

Premium

Keeping Tabs on the Damage from a Cratering Valeant

Pershing Square and Paulson & Co. have taken big hits. But savvy stock picking like ValueAct Capital’s can at least limit the damage.

Stephen Taub

March 21, 2016

Premium

Valeant’s Winners and Losers

The troubled drugmaker takes another plunge as it reduces guidance. Here’s a quick survey of the firms that are taking a bath and those that look like geniuses.

Stephen Taub

March 16, 2016

Premium

ValueAct Grows Its Cash Pile, but Not for Dry Powder

Firm co-founder Jeffrey Ubben tells Alpha that his firm isn’t finding much to buy these days.

Stephen Taub

March 7, 2016

Premium

ValueAct Is Seeking Longer-Term Capital

The firm, now down for the year after its big losses on Valeant, is looking to raise money for a longer lockup structure that will charge lower fees.

Stephen Taub

November 24, 2015